A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza

Trends in Microbiology

Volumn 24, Issue 12, 2016, Pages 933-943

  Ramakrishnan, Boopathy ^a   Viswanathan, Karthik ^a   Tharakaraman, Kannan ^b   Dančík, Vlado ^c   Raman, Rahul ^b   Babcock, Gregory J ^a   Shriver, Zachary ^a   Sasisekharan, Ram ^b  

^a VISTERRA INC   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; FC RECEPTOR; INFLUENZA VIRUS HEMAGGLUTININ; INFLUENZA VIRUS HEMAGGLUTININ 2; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANTIBODY DEPENDENT ENHANCEMENT; ANTIGEN BINDING; ANTIVIRAL ACTIVITY; BACTERIAL KINETICS; HUMAN; INFLUENZA; INFLUENZA VIRUS; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REVIEW; STRUCTURE ANALYSIS; VIRUS KINETICS; VIRUS NEUTRALIZATION; VIRUS PATHOGENESIS; VIRUS REPLICATION; BIOLOGICAL MODEL; DENGUE; IMMUNOLOGY; MOLECULAR MODEL; VIREMIA; VIROLOGY; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; DENGUE; EPITOPES; HUMANS; INFLUENZA, HUMAN; MODELS, BIOLOGICAL; MODELS, MOLECULAR; VIREMIA; VIRUS DISEASES;

EID: 84991282630     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2016.09.003     Document Type: Review

References (70)

1. 1 Lu, C.L., et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352 (2016), 1001–1004.
2. 2 Schoofs, T., et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352 (2016), 997–1001.
3. 3 Laserson, U., et al. High-resolution antibody dynamics of vaccine-induced immune responses. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), 4928–4933.
4. 4 Lingwood, D., et al. Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 489 (2012), 566–570.
5. 5 Pappas, L., et al. Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature 516 (2014), 418–422.
6. 6 Sobolev, O., et al. Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. Nat. Immunol. 17 (2016), 204–213.
7. 7 Kreijtz, J.H., et al. Immune responses to influenza virus infection. Virus Res. 162 (2011), 19–30.
8. 8 Andrews, S.F., et al. Immune history profoundly affects broadly protective B cell responses to influenza. Science Transl. Med., 7, 2015, 316ra192.
9. 9 Schmidt, A.G., et al. Immunogenic stimulus for germline precursors of antibodies that engage the influenza hemagglutinin receptor-binding site. Cell Rep. 13 (2015), 2842–2850.
10. 10 Wang, T.T., et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 18979–18984.
11. 11 Brandenburg, B., et al. Mechanisms of hemagglutinin targeted influenza virus neutralization. PLoS ONE, 8, 2013, e80034.
12. 12 Otterstrom, J.J., et al. Relating influenza virus membrane fusion kinetics to stoichiometry of neutralizing antibodies at the single-particle level. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), E5143–E5148.
13. 13 DiLillo, D.J., et al. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J. Clin. Invest. 126 (2016), 605–610.
14. 14 DiLillo, D.J., et al. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat. Med. 20 (2014), 143–151.
15. 15 Impagliazzo, A., et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349 (2015), 1301–1306.
16. 16 Yassine, H.M., et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 21 (2015), 1065–1070.
17. 17 Henry Dunand, C.J., et al. Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection. Cell Host Microbe 19 (2016), 800–813.
18. 18 Ekiert, D.C., et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324 (2009), 246–251.
19. 19 Ekiert, D.C., et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333 (2011), 843–850.
20. 20 Corti, D., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333 (2011), 850–856.
21. 21 Dreyfus, C., et al. Highly conserved protective epitopes on influenza B viruses. Science 337 (2012), 1343–1348.
22. 22 Tharakaraman, K., et al. A broadly neutralizing human monoclonal antibody is effective against H7N9. Proc. Natl. Acad. Sci. U.S.A. 112 (2015), 10890–10895.
23. 23 Okuno, Y., et al. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 67 (1993), 2552–2558.
24. 24 Sui, J., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16 (2009), 265–273.
25. 25 Nakamura, G., et al. An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe 14 (2013), 93–103.
26. 26 Wang, T.T., et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS pathog., 6, 2010, e1000796.
27. 27 Tan, G.S., et al. A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J. Virol. 86 (2012), 6179–6188.
28. 28 Tharakaraman, K., et al. Broadly neutralizing influenza hemagglutinin stem-specific antibody CR8020 targets residues that are prone to escape due to host selection pressure. Cell Host Microbe 15 (2014), 644–651.
29. 29 Jang, Y.H., Seong, B.L., Options and obstacles for designing a universal influenza vaccine. Viruses 6 (2014), 3159–3180.
30. 30 Whitehead, S.S., et al. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 5 (2007), 518–528.
31. 31 Halstead, S.B., In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J. Infect. Dis. 140 (1979), 527–533.
32. 32 Ponnuraj, E.M., et al. Antibody-dependent enhancement, a possible mechanism in augmented pulmonary disease of respiratory syncytial virus in the Bonnet monkey model. J. Infect. Dis. 187 (2003), 1257–1263.
33. 33 Osiowy, C., et al. Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants. Clin. Diagnost. Lab. Immunol. 1 (1994), 670–677.
34. 34 Gauger, P.C., et al. Enhanced pneumonia and disease in pigs vaccinated with an inactivated human-like (delta-cluster) H1N2 vaccine and challenged with pandemic 2009 H1N1 influenza virus. Vaccine 29 (2011), 2712–2719.
35. 35 Khurana, S., et al. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Science Transl. Med., 5, 2013, 200ra114.
36. 36 Gould, E.A., Buckley, A., Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence. J. Gen Virol. 70 (1989), 1605–1608.
37. 37 Gould, E.A., et al. Immune enhancement of yellow fever virus neurovirulence for mice: studies of mechanisms involved. J. Gen. Virol. 68 (1987), 3105–3112.
38. 38 Phillpotts, R.J., et al. Antibody-dependent enhancement of tick-borne encephalitis virus infectivity. J. Gen. Virol. 66 (1985), 1831–1837.
39. 39 Ubol, S., Halstead, S.B., How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin. Vaccine Immunol. 17 (2010), 1829–1835.
40. 40 Halstead, S.B., Immune enhancement of viral infection. Prog. Allergy 31 (1982), 301–364.
41. 41 de Alwis, R., et al. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS pathog., 10, 2014, e1004386.
42. 42 Zellweger, R.M., Shresta, S., Mouse models to study dengue virus immunology and pathogenesis. Front. Immunol., 5, 2014, 151.
43. 43 Caballero, M.T., et al. TLR4 genotype and environmental LPS mediate RSV bronchiolitis through Th2 polarization. J. Clin. Invest. 125 (2015), 571–582.
44. 44 Ochiai, H., et al. Antibody-mediated growth of influenza A NWS virus in macrophagelike cell line P388D1. J. Virol. 62 (1988), 20–26.
45. 45 Ochiai, H., et al. Infection enhancement of influenza A NWS virus in primary murine macrophages by anti-hemagglutinin monoclonal antibody. J. Med. Virol. 36 (1992), 217–221.
46. 46 Skowronski, D.M., et al. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLoS Med., 7, 2010, e1000258.
47. 47 Swalley, S.E., et al. Full-length influenza hemagglutinin HA2 refolds into the trimeric low-pH-induced conformation. Biochemistry 43 (2004), 5902–5911.
48. 48 Fontana, J., et al. Structural changes in Influenza virus at low pH characterized by cryo-electron tomography. J. Virol. 86 (2012), 2919–2929.
49. 49 Wyrzucki, A., et al. Alternative recognition of the conserved stem epitope in influenza A virus hemagglutinin by a VH3-30-encoded heterosubtypic antibody. J. Virol. 88 (2014), 7083–7092.
50. 50 Short, K.R., et al. The fate of influenza A virus after infection of human macrophages and dendritic cells. J. Gen. Virol. 93 (2012), 2315–2325.
51. 51 Sidorenko, Y., Reichl, U., Structured model of influenza virus replication in MDCK cells. Biotechnol. Bioeng. 88 (2004), 1–14.
52. 52 Nunes-Correia, I., et al. Interactions of influenza virus with cultured cells: detailed kinetic modeling of binding and endocytosis. Biochemistry 38 (1999), 1095–1101.
53. 53 Fei, Y., et al. Characterization of receptor binding profiles of influenza a viruses using an ellipsometry-based label-free glycan microarray assay platform. Biomolecules 5 (2015), 1480–1498.
54. 54 Bruhns, P., Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119 (2012), 5640–5649.
55. 55 Crapo, J.D., et al. Cell number and cell characteristics of the normal human lung. Am. Rev. Resp. Dis. 126 (1982), 332–337.
56. 56 Antal-Szalmas, P., et al. Quantitation of surface CD14 on human monocytes and neutrophils. J. Lleukocyte Biol. 61 (1997), 721–728.
57. 57 Thornburg, N.J., et al. H7N9 influenza virus neutralizing antibodies that possess few somatic mutations. J. Clin. Invest. 126 (2016), 1482–1494.
58. 58 Baccam, P., et al. Kinetics of influenza A virus infection in humans. J. Virol. 80 (2006), 7590–7599.
59. 59 Boianelli, A., et al. Modeling Influenza Virus Infection: A Roadmap for Influenza Research. Viruses 7 (2015), 5274–5304.
60. 60 Dobrovolny, H.M., et al. Assessing mathematical models of influenza infections using features of the immune response. PLoS ONE, 8, 2013, e57088.
61. 61 Cao, P., et al. Innate immunity and the inter-exposure interval determine the dynamics of secondary influenza virus infection and explain observed viral hierarchies. PLoS Comput. Biol., 11, 2015, e1004334.
62. 62 Li, Y., Handel, A., Modeling inoculum dose dependent patterns of acute virus infections. J. Theor. Biol. 347 (2014), 63–73.
63. 63 Collins, P.L., Graham, B.S., Viral and host factors in human respiratory syncytial virus pathogenesis. J. Virol. 82 (2008), 2040–2055.
64. 64 Connors, M., et al. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 68 (1994), 5321–5325.
65. 65 Hussell, T., et al. CD8 + T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. Eur. J. Immunol. 27 (1997), 3341–3349.
66. 66 Johnson, T.R., et al. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J. Virol. 78 (2004), 6024–6032.
67. 67 Boyoglu-Barnum, S., et al. Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice. J. Virol. 88 (2014), 10569–10583.
68. 68 Deng, N., et al. Cytokine diversity in the Th1-dominated human anti-influenza response caused by variable cytokine expression by Th1 cells, and a minor population of uncommitted IL-2 + IFNgamma- Thpp cells. PLoS ONE, 9, 2014, e95986.
69. 69 Wohlleben, G., et al. Influenza A virus infection inhibits the efficient recruitment of Th2 cells into the airways and the development of airway eosinophilia. J. Immunol. 170 (2003), 4601–4611.
70. 70 Baranovich, T., et al. The hemagglutinin stem-binding monoclonal antibody VIS410 controls influenza virus-induced acute respiratory distress syndrome. Antimicrob. Agents Chemother. 60 (2016), 2118–2131.